Figure 1: RF therapy of prostate
Figure 1: RF therapy of prostate
References
1. Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004;171(pt 1):2336-2340.
In this study of 65 patients, 13 were evaluated five years after RF therapy. Only 14% of the 65 patients needed further treatment for BPH symptoms and went on to have transurethral resection of the prostate surgical procedure (TURP).
2. Zlotta A, Giannakopoulos X, Maehlum O, Ostrem T, Schulman C. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcomes up to five years from three centers. Eur Urol. 2003;44:89-93.
In this study of 188 patients, 121 were evaluated five years after RF therapy. More than 75% did not need additional treatment for BPH symptoms.
PROSTIVA® RF THERAPY
Indications: The PROSTIVA RF Therapy System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men over the age of 50 with prostate sizes between 20 and 50 cm3.
Adverse Events: Possible side effects include obstruction (blockage), urinary retention, bleeding, blood in urine, pain/discomfort, urgency to urinate, increased urinary frequency, and urinary tract infection. Patients may also experience a minor burning sensation when urinating for one to two weeks following the treatment.
CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. For a listing of indications, contraindications, precautions and warnings, please refer to the System User Guide. For additional information about PROSTIVA RF Therapy, please see the complete PROSTIVA RF Therapy Safety Data.
Page Sponsored by Medtronic Urology
bph treatment, go to go therapy, LUTs treatment, office treatment, minimally invasive treatment, TUNA, weak stream, getting up at night, nocturia, prostatic hyperplasia treatment, difficulty urinating, problems peeing
Medtronic PROSTIVA® RF Therapy for Symptomatic BPH
Medtronic PROSTIVA RF Therapy is a safe, in-office procedure with few side effects. The therapy uses low-level radio frequency (RF) energy to destroy excess prostate tissue.
PROSTIVA RF Therapy has been shown in clinical studies to improve urine flow and relieve urinary symptoms for five years in patients with benign prostatic hyperplasia (BPH).1,2
This therapy is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to BPH in men over the age of 50 with prostate sizes between 20 and 50 cm3.
PROSTIVA RF Therapy is an in-office procedure that is usually done with local anesthesia only. The procedure generally takes less than one hour, with some additional preparation and recovery time required.
During the procedure, RF energy is delivered via two electrodes into the prostate tissue for selective ablation of specific areas. This produces a localized coagulated necrotic lesion, which may result in BPH symptom relief and improved urine flow.
RF therapy is associated with few side effects and adverse events.
For more information about PROSTIVA RF Therapy, visit Medtronic.
For online resources for information about PROSTIVA RF Therapy, visit Medtronic Connect.
